TrianglePUBLICATIONS · 39250926
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Haematol
- Publication date
- 2024 Nov
- First author
- Cook G
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Cook G
- type
- Author
- name
- Ashcroft AJ
- type
- Author
- name
- Senior E
- type
- Author
- name
- Olivier C
- type
- Author
- name
- Hockaday A
- type
- Author
- name
- Richards J
- type
- Author
- name
- Cavenagh JD
- type
- Author
- name
- Snowden JA
- type
- Author
- name
- Drayson MT
- type
- Author
- name
- de Tute R
- type
- Author
- name
- Roberts L
- type
- Author
- name
- Owen RG
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Cook G
- type
- Author
- name
- Ashcroft AJ
- type
- Author
- name
- Senior E
- type
- Author
- name
- Olivier C
- type
- Author
- name
- Hockaday A
- type
- Author
- name
- Richards J
- type
- Author
- name
- Cavenagh JD
- type
- Author
- name
- Snowden JA
- type
- Author
- name
- Drayson MT
- type
- Author
- name
- de Tute R
- type
- Author
- name
- Roberts L
- type
- Author
- name
- Owen RG
- type
- Author
- bibliography ids
- nci-bib-39749d975f4b95b4850924d6
- book metadata
- content sha256
- 3665b29ae296996edd5b6975243092ca262f3e2ff13b9791bb24dbea8d91cf09
- document type
- citation
- dois
- 10.1016/S2352-3026(24)00249-7
- electronic publication date
- display
- 2024 Sep 6
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39250926
- immutable id
- pubmed:39250926@3665b29ae296996edd5b6975243092ca262f3e2ff13b9791bb24dbea8d91cf09
- journal
- abbreviation
- Lancet Haematol
- issn electronic
- 2352-3026
- issn print
- Source null
- issue
- 11
- name
- The Lancet. Haematology
- nlm unique id
- 101643584
- pages
- e816-e829
- volume
- 11
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39250926
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- 7c7f76df607e2bada2e98c99d32f2f1b9a2533a7a5521a4b81cf079e435c43fc
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Nov
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Randomized Controlled Trial
- Clinical Trial, Phase III
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Preserved source evidence · Not medical advice